JPMAM and UBS launch genetic therapies fund

JP Morgan Asset Management (JPMAM) has partnered with UBS Wealth Management to launch a fund focused on investing in genetic therapies.

The fund, which JPMAM calls an industry first, combines machine learning and active management and uses research from UBS Wealth Management.

The JP Morgan Funds – Thematics – Genetic Therapies will be co-managed by Yazann Romahi, Berkan Sesen and Aijaz Hussein.

According to JPMAM, genetic therapies represent a “once-in-a-generation breakthrough” in the world of medicine.

Genetic therapy treatments offer the hope of a cure for patients with serious inherited diseases by modifying genetic information to address the underlying cause of the disease, the firm said.

Mark Haefele, chief investment officer at UBS Global Wealth Management, said: “Genetic therapies could develop into a profoundly disruptive technology for the pharmaceutical and biotechnology industry.

“Positioning portfolios to capture the economic benefits of disruption, while hedging or mitigating its effects on other assets, supports our goal to help our clients protect and grow their wealth over generations.”

©2019 funds europe

HAVE YOU READ?

THOUGHT LEADERSHIP

Innovative US companies are providing some of the solutions to the climate crisis and transition to a more sustainable economy. We see potential opportunities in areas including renewable energy and…
FIND OUT MORE
This white paper outlines key challenges impeding the growth of private markets and explores how technological innovation can provide solutions to unlock access to private market funds for a growing…
DOWNLOAD NOW

IRELAND SPOTLIGHT

Visit our dedicated Ireland channel for all the latest news and analysis on the country's investment industry.
READ MORE

PRIVATE MARKETS FUND ADMIN REPORT

Private_Markets_Fund_Admin_Report

LATEST PODCAST